Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
459 Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1–positive metastatic NSCLC
Compose a Response to This Article
Other responses
No responses have been published for this article.